# Johann de Bono

Source: https://onco.cc/people/johann-de-bono/  
OnCo record `johann-de-bono` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Johann de Bono led the trials that brought abiraterone and olaparib to prostate cancer patients.

## Summary

Johann de Bono is Regius Professor of Cancer Research at The Institute of Cancer Research and Head of the Drug Development Unit at The Royal Marsden, one of Europe's largest phase 1 units. His specialisms are prostate cancer, early drug development, PARP inhibitors and androgen receptor targeting. He led the pivotal COU-AA-301 trial of abiraterone in metastatic castration-resistant prostate cancer and PROfound, the trial of olaparib in prostate cancer with homologous recombination repair mutations, both reported in the New England Journal of Medicine. These trials brought abiraterone and olaparib to prostate cancer patients. His ICR profile and PubMed listing are linked.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Regius Professor of Cancer Research, ICR; Head of Drug Development Unit, Royal Marsden
- Specialisms: Prostate cancer; Early drug development; PARP inhibitors; Androgen receptor targeting

## Sources

- ICR profile: https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-johann-de-bono
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=de%20Bono%20JS%5BAuthor%5D%20prostate

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [The Institute of Cancer Research](https://onco.cc/institutions/icr-london/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/)
- trials: [PROfound](https://onco.cc/trials/profound/)
- key papers: [KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/), [Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven](https://onco.cc/key-papers/paper-attard-abiraterone-phase-1-cyp17-jco-2008/), [PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy](https://onco.cc/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/), [STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer](https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/), [SU2C-PCF: integrative clinical genomics of advanced prostate cancer](https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/), [TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer](https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/), [TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel](https://onco.cc/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://onco.cc/key-papers/paper-vision-nejm-2021/)
- people: [Dearbhaile Collins](https://onco.cc/people/dearbhaile-collins/), [Nicholas van As](https://onco.cc/people/nicholas-van-as/), [Rosalind Eeles](https://onco.cc/people/ros-eeles/)

---
JSON: https://onco.cc/api/v1/entities/johann-de-bono.json